Valsartan/Hydrochlorothiazide Tablets
Pre-Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- SPE2D2-25-R-0014
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Not on record
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical is preparing to issue a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which are pharmaceutical preparations used in medical treatment. The solicitation will cover five specific tablet combinations in 90-count bottles, targeting customers from the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. This will be a fully competitive, unrestricted acquisition utilizing FAR part 12 for commercial items, with all sources eligible to submit proposals. The contract will be a firm-fixed price requirements type, structured with a one-year base period and four potential one-year option periods. Interested parties are advised to contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for questions, and to set up automated notifications through the DLA Bid Board System (DIBBS) and Sam.Gov.
The pre-solicitation notice indicates no specific set-aside designations for this procurement, meaning it is open to all qualifying vendors. The projected solicitation date is May 2025, though DLA reserves the right to adjust this timeline. While specific award values are not detailed, the contract will establish a national supply source for the specified pharmaceutical tablets. The contract will be procured through DLA and VA prime vendor programs, with annual usage estimates to be provided in the solicitation's Schedule of Supplies. The specific tablet combinations include Valsartan dosages of 80 MG, 160 MG, and 320 MG, paired with Hydrochlorothiazide dosages of 12.5 MG and 25 MG. Vendors should monitor DIBBS and Sam.Gov for the full solicitation and detailed requirements when published.
Notice text
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets. Procurement details follow.
Valsartan 160 MG-Hydrochlorothiazide 12.5 MG Tablets, Valsartan 160 MG-Hydrochlorothiazide 25 MG Tablets, Valsartan 320 MG-Hydrochlorothiazide 12.5 MG Tablets, Valsartan 320 MG-Hydrochlorothiazide 25 MG Tablets, and Valsartan 80 MG-Hydrochlorothiazide 12.5 MG Tablets in 90 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Kyle Lewicki at (215) 737-3696, (kyle.lewicki@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is May of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Valsartan/Hydrochlorothiazide Tablets | Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Sodium Bicarbonate Injection Vial Restricted to Made in America | National Acquisition Center | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity